Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QR-421a in USH2A exon 13 retinitis pigmentosa with advanced vision loss
2021-002729-74Phase 2Terminated
- Sponsor
- ProQR Therapeutics
- Start
- Sep 2021
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ultevursen in retinitis pigmentosa (RP) (2 arms), sponsored by ProQR Therapeutics. Primary endpoint: Mean change from baseline in best corrected visual acuity. Started Sep 2021; status: terminated.
02
Drugs
ultevursen
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on 2021-002729-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002729-74.